The grant, called a National Institutes of Health (NIH) Cooperative Agreement Award, is given by the NIH as part of its Protein Structure Initiative (PSI).
The award provides five years of renewed funding for a consortium administered by Structural GenomiX. The company expects to retain approximately 50% of the funding with the remainder to be distributed to institution collaborators.
“We are partnering with some of the finest medical research institutions in the world,” said Dr Stephen Burley, Structural GenomiX’s chief scientific officer and senior vice president.
Under Dr Burley as principal investigator, Structural GenomiX will lead the overall research efforts under this NIH Award and will be responsible for primary oversight and administration of activities by the institution collaborators, as well as all gene cloning and expression, purification, and biophysical characterization of target proteins.
The company plans to use its proprietary technology platform to produce high quality and well characterized proteins for crystallization and structure determination. In addition, Structural GenomiX will provide access to its state-of-the-art X-ray beamline for structure determination efforts.